Clinical Trials
10 trialsNCT06934928 2026-06-04
Assessing the Efficacy of Repeat, Monthly Treatments of Alexandrite Laser for NF1-associated Cutaneous Neurofibromas (cNFs)
Massachusetts General Hospital
Phase NA Suspended
NCT02211768 2026-05-29
Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT07102394 2026-05-08
Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1
Johns Hopkins University
Phase 1 Recruiting
NCT03962543 2026-05-06
ReNeu
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 2 Active not recruiting
NCT07233408 2026-02-27
Tailoring an Online Platform to Promote Evidence-Based Care for Adults With Neurofibromatosis 1 and Low Health Literacy
Massachusetts General Hospital
Phase NA Recruiting
NCT03873610 2025-12-26
Resiliency Training in Adolescents With NF1 and NF2
Massachusetts General Hospital
Phase NA Active not recruiting
NCT03406208 2025-12-24
Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing
Massachusetts General Hospital
Phase NA Completed
NCT06961565 2025-12-04
PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas
Pasithea Therapeutics Corp.
Phase 1 Recruiting
NCT07237100 2025-11-19
Mirdametinib in Patients With Advanced NF1-mutant Melanoma
Sutter Health
Phase 2 Recruiting
NCT06262113 2025-10-03
A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1
Massachusetts General Hospital
Phase NA Recruiting